Celltrion, Foreign Investors Net Buy 431,186 Shares in Last 5 Days... Stock Price at 368,000 Won (+13.58%)

As of 11:31 AM on the 1st, Celltrion is trading at 368,000 KRW, up 13.58% from the previous day. The trading volume is 4,440,981 shares, which is 420.45% of the previous day's volume. Celltrion is known as a protein and biopharmaceutical manufacturing company.

On January 28, Hana Financial Investment researcher Sun Min-jung stated, "After the announcement of the Phase 2 clinical trial results of the COVID-19 antibody treatment Regkirona, Celltrion's stock price is currently uncertain due to 1) whether Regkirona will enter the U.S. market, and 2) the expansion of sales of Remsima SC. Therefore, the stock price may remain within a range for the time being. Given the nature of the biosimilar business, growth can be expected through the annual launch of new products. This year, new products are scheduled to be launched sequentially every year, including Uplyma, a Humira biosimilar newly launched in Europe," and set Celltrion's target price at 364,000 KRW.

Over the past five days, individual investors have net sold 393,564 shares of Celltrion, while foreigners and institutions have net bought 430,186 shares and net sold 38,959 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an article automation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.